Sepsis Management Analysis, 2020 Report - Treatments Focused Towards Antibiotics, Inhibitors, Antibodies, Peptides, Recombinant Proteins, Antibacterial, Antifungal, Antivirals, Vaccines, & Probiotics

Dublin, IRELAND


Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Analysing Sepsis Management Part II: Treatments" report has been added to ResearchAndMarkets.com's offering.

This research study begins by highlighting the current status of sepsis treatment, such as antibiotics used with different kinds of pathogens along with antifungal and antiviral drugs used to treat infections; and also talks about the importance of fluid resuscitation and oxygen therapy in severe sepsis. A brief introduction to the course of sepsis development, the most important pathogen involved in sepsis and commonly affected body sites and associated mortality rates have discussed.

Sepsis is a life-threatening condition caused by overactivation of the host immune system upon infections which may lead to organ failure and potentially death. World Health Organization designates sepsis as a global public health priority. Several studies conducted to understand the molecular basis of sepsis, septic shock, and organ failure. Despite extensive preclinical and clinical studies conducted over the past few decades, no significant improvement has observed in sepsis management.

Lack of effective therapeutics raises the question about our understanding of sepsis pathophysiology. Another challenge comes with the heterogeneous nature of sepsis which depends on several factors, such as the pathogen causing infection and age, genetic make-up, existing medical condition, and lifestyle of the person. A further challenge comes with a measurement of the success of novel therapeutics.

This study highlights some of the most important aspects considered to improve the current understanding and underlying mechanisms of sepsis, importance of preclinical and clinical studies, integration of sepsis specific biomarker in therapeutics, detecting biological signals and gene expression levels and designing novel interventions such as immunomodulatory and personalized approaches.

Moreover, this study covers new sepsis treatment approaches such as phage therapy, cellular immunotherapy, antibody therapeutics, recombinant protein therapeutics, peptide therapeutics, microbial therapeutics, and vaccines as well as newly designed receptor blocker, receptor inhibitors, agonist, and alkaloids. A short introduction to clinical updates and patent landscape for sepsis therapeutics has provided. The study concludes with an emphasis on adopting new technologies to develop our understanding of sepsis that will help design breakthrough therapeutics.

Key Topics Covered:

1. STRATEGIC IMPERATIVES
1.2 The Strategic Imperative
1.3 The Impact of the Top Three Strategic Imperatives on Sepsis Therapeutics Industry
1.4 About the Growth Pipeline Engine
1.5 Growth Opportunities Fuel the Growth Pipeline Engine

2. EXECUTIVE SUMMARY
2.1 Research Scope: Sepsis Therapeutics
2.2 Analysis Framework: Core Value
2.3 Research Methodology: Five Steps Toward Success
2.4 Key Findings of novel Sepsis therapeutics

3. TECHNOLOGY SNAPSHOT
3.1 Research Scope: Current Status and Challenges of Sepsis Therapeutics
3.2 Therapeutic strategies covered
3.3 Pathogenesis of Sepsis
3.4 Common bacteria and body sites involved in sepsis and associated mortality rates

4. EXISTING SEPSIS THERAPEUTICS
4.1 Therapies for sepsis and septic shock management
4.2 Sepsis Treatment for antibiotic resistant bacteria
4.3 Antifungals treatment for sepsis
4.4 Treatment of viral sepsis

5. UPCOMING SEPSIS THERAPEUTICS
5.1 Advances in sepsis and septic shock therapeutics
5.2 Phage Therapy for severe sepsis
5.3 Cellular Immunotherapy for sepsis
5.4 Antibody-based immunotherapy for sepsis
5.5 Protein therapeutics for sepsis
5.6 Peptide Therapeutics for sepsis
5.7 Vaccines for sepsis
5.8 Novel receptor blocker and probiotic for sepsis treatment
5.9 Alkaloids and agonist for sepsis treatment

6. SEPSIS CLINICAL TRIALS
6.1 Interventions Used for Sepsis Management
6.2 Clinical Landscape for Sepsis Management
6.3 Phase 3 Clinical Trials for Sepsis Management
6.4 Phase 3 Clinical Trials for Biological therapeutics for Sepsis
6.5 Drugs in Phase 3 Clinical Trials for Sepsis Management

7. SEPSIS PATENT LANDSCAPE
7.1 Published patent count for sepsis is witnessing steady growth

8. GROWTH OPPORTUNITIES
8.1 Growth Opportunity: New Knowledge and Technologies Are Needed to Better Understand Sepsis, 2020

9. KEY INDUSTRY INFLUENCERS
9.1 Industry Interactions

For more information about this report visit https://www.researchandmarkets.com/r/j4qki1

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

 

Contact Data